|
KMID : 1143420200130493484
|
|
Public Health Weekly Report
2020 Volume.13 No. 49 p.3484 ~ p.3494
|
|
|
Importance of Standardization of Lipid test in the Management of Dyslipidemia
|
|
Yun Yeo-Min
|
|
|
Abstract
|
|
|
Dyslipidemia is charaterized by an elevation of serum cholesterol, triglycerides, or a low high-density lipoprotein(HDL) cholesterol level which can increase the risk of developing atherosclerosis. Dyslipidemia is one of the four major risk factors hypertension, diabetes, and smoking for cardiovascular disease (CVD) development. Since dyslipidemia is generally asymptomatic, a screening lipid test is essential to identify patients requiring lipid lowering treatment. The recommended screening tests for dyslipidemia are fasting lipid samples taken every 4 to 6 years by all adults older than 21 years of age and by younger individuals that have CVD risk factors (such as a family history of premature CVD or severe dyslipidemia, or a history of smoking, abdominal obesity, chronic kidney disease and chronic inflammatory diseases).
Securing the reliability of lipid measurements is essential because lipid test results are used as important criteria for the diagnosis of dyslipidemia and are used as treatment goals for the prevention and management of CVD. The Adult Treatment Panel (ATP) guidelines published by the National Cholesterol Education Program (NCEP) of National Institutes of Health (NIH) provide allowable criteria for measurement errors of routine lipid assays for the management of dyslipidemia.
However, despite the importance of these tests, it is not easy to develop an in vitro diagnostic test assay that reflects the exact lipid levels of dyslipidemia due to the complex characteristics of lipoproteins. Therefore, international efforts were made to standardize lipid test assays to ensure equivalence and to improve the accuracy of lipid test results.
In January 2020, the National Medical Reference Laboratory (NMRL) of the Korea Disease Control and Prevention Agency (KDCA) obtained international certification through the Cholesterol Reference Method Laboratory Network (CRMLN) for HDL cholesterol and low-density lipoprotein (LDL) cholesterol. In addition to the existing total cholesterol and triglycerides the NMRL started participating in the CRMLN HDL cholesterol DCM certification survey from July 2020. This study concluded that even with the active cooperation and continuous efforts by the NMRL of KDCA and related expert academic organizations including the Korean Society for Laboratory Medicine support is still needed.
|
|
|
KEYWORD
|
|
|
Dyslipoproteinemia, Lipid test, Standardization
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|